What is HC Wainwright's Estimate for CGTX FY2025 Earnings?

Key Points

• HC Wainwright has upgraded its earnings per share estimate for Cognition Therapeutics for FY2025 from ($0.36) to ($0.33) and maintains a "Buy" rating with a price target of $3.00.
• Cognition Therapeutics reported ($0.11) EPS for the last quarter, exceeding the consensus estimate of ($0.12).
• Institutional investors currently hold 43.35% of Cognition Therapeutics' stock, showing increased confidence among hedge funds in recent trading activities.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Cognition Therapeutics in a research report issued on Monday, August 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.33) for the year, up from their previous estimate of ($0.36). HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for Cognition Therapeutics' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics' Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.15) EPS.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01.

CGTX has been the subject of several other research reports. Wall Street Zen lowered Cognition Therapeutics to a "strong sell" rating in a research report on Saturday, July 12th. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price target on shares of Cognition Therapeutics in a report on Friday, August 8th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Cognition Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $2.83.

Cognition Therapeutics Price Performance

Shares of NASDAQ:CGTX traded up $0.25 during trading hours on Thursday, hitting $1.47. 3,439,437 shares of the company's stock traded hands, compared to its average volume of 4,291,438. Cognition Therapeutics has a 1 year low of $0.22 and a 1 year high of $1.47. The business has a fifty day moving average price of $0.54 and a 200-day moving average price of $0.47. The firm has a market capitalization of $107.64 million, a P/E ratio of -2.17 and a beta of 1.00.

Institutional Trading of Cognition Therapeutics

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Cognition Therapeutics by 8.9% during the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company's stock worth $247,000 after buying an additional 28,705 shares during the last quarter. Voss Capital LP purchased a new position in Cognition Therapeutics in the 4th quarter valued at approximately $351,000. Two Sigma Investments LP boosted its position in Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company's stock valued at $38,000 after buying an additional 42,321 shares during the period. CM Management LLC boosted its position in Cognition Therapeutics by 100.0% in the 1st quarter. CM Management LLC now owns 400,000 shares of the company's stock valued at $168,000 after buying an additional 200,000 shares during the period. Finally, Northeast Financial Consultants Inc lifted its position in shares of Cognition Therapeutics by 158.6% during the 1st quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company's stock worth $27,000 after purchasing an additional 38,851 shares during the last quarter. Institutional investors and hedge funds own 43.35% of the company's stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.